LKB1 and Mammalian Target of Rapamycin As Predictive Factors for the Anticancer Efficacy of Metformin
- 1 December 2009
- journal article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 27 (34), e226
- https://doi.org/10.1200/jco.2009.25.3963
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Metformin and Pathologic Complete Responses to Neoadjuvant Chemotherapy in Diabetic Patients With Breast CancerJournal of Clinical Oncology, 2009
- Metformin in Breast Cancer: Time for ActionJournal of Clinical Oncology, 2009
- Dietary Energy Balance Modulates Signaling through the Akt/Mammalian Target of Rapamycin Pathways in Multiple Epithelial TissuesCancer Prevention Research, 2008
- Phosphorylation of LKB1 at Serine 428 by Protein Kinase C-ζ Is Required for Metformin-Enhanced Activation of the AMP-Activated Protein Kinase in Endothelial CellsCirculation, 2008
- Metformin Inhibits Mammalian Target of Rapamycin–Dependent Translation Initiation in Breast Cancer CellsCancer Research, 2007
- A role for LKB1 gene in human cancer beyond the Peutz–Jeghers syndromeOncogene, 2007
- Epigenetic inactivation of LKB1 in primary tumors associated with the Peutz-Jeghers syndromeOncogene, 2000
- A serine/threonine kinase gene defective in Peutz–Jeghers syndromeNature, 1998